Increase in Lipoprotein (a) levels during COVID-19 hospitalization tied to VTE risk: Study
Netherlands: Results from a pilot study published in the journal Atherosclerosis showed that in patients hospitalized with COVID-19, the levels of lipoprotein(a) increase threefold during hospitalization. And, an increase in Lp(a) levels during the COVID-19 acute phase was strongly linked with venous thromboembolism (VTE) incidence. In contrast to this, the change in the inflammatory biomarkers interleukin (IL)-6 and CRP was not associated with VTE incidence.
In patients with Coronavirus disease 2019 (COVID-19), thrombosis is shown to be a major driver of mortality and adverse outcomes. Hypercoagulability may be related to the cytokine storm associated with COVID-19, which is driven mainly by IL-6. An increase in Lp(a) levels following IL-6 upregulation and Lp(a) has anti-fibrinolytic properties.
Against the above background, Erik S.G. Stroes, University of Amsterdam, Amsterdam, the Netherlands, and colleagues aimed to investigate whether Lp(a) elevation may contribute to the pro-thrombotic state hallmarking COVID-19 patients.
For this purpose, the researchers measured Lp(a), IL-6, and C-reactive protein (CRP) levels in 219 hospitalized patients with COVID-19. The baseline biomarkers and increases during admission were related to VTE incidence and clinical outcomes.
Based on the study, the researchers found the following:
· Lp(a) levels increased significantly by a mean of 16.9 mg/dl in patients with COVID-19 during the first 21 days after admission.
· Serial Lp(a) measurements were available in 146 patients.
· In the top tertile of Lp(a) increase, 56.2% of COVID-19 patients experienced a VTE event compared to 18.4% in the lowest tertile (RR 3.06).
· This association remained significant after adjusting for age, sex, IL-6 and CRP increase, and a number of measurements.
· Increases in IL-6 and CRP were not associated with VTE. Increase in Lp(a) was strongly correlated with increase in IL-6 (r = 0.44).
To conclude, increases in Lp(a) levels during the acute phase of COVID-19 were strongly associated with VTE incidence. The acute increase in anti-fibrinolytic Lp(a) may tilt the balance to VTE in patients hospitalized for COVID-19.
Reference:
The study titled, "Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study," was published in the journal Atherosclerosis.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.